Search Results

Business

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx’s Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

Phio Pharmaceuticals Corp. today announced its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual.

May 24, 2023

·

5 min read

Business

Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it has entered into a clinical development collaboration with AgonOx, Inc.

March 1, 2021

·

7 min read

Business

ImmunoPrecise’s Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics

Entered into an LOI to form a Joint Venture as it partners in the continued development of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx, a clinical-stage biopharma company. AgonOx specializes in identifying and developing immuno-oncology therapeutics.

September 24, 2019

·

5 min read

Business

Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration With AgonOx

October 4, 2016

·

3 min read

Drug Development

AgonOx’s OX40 Platform Being Utilized In MedImmune’s Phase 1 OX40 Agonist Study

October 20, 2014

·

1 min read

FDA

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to proceed with a clinical trial of Phio’s lead product candidate, PH-762.

May 16, 2023

·

4 min read

Business

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the year ended December 31, 2022 and provided a business update.

March 22, 2023

·

9 min read

Business

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the quarter ended March 31, 2023 and provided a business update.

May 11, 2023

·

7 min read

Genetown

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals Corp. today announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 8 - 12, 2022.

October 6, 2022

·

5 min read

Business

AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy

October 31, 2011

·

3 min read